CATALYST BIOSCIENCES, INC. acquired GNI’s proprietary new chemical entity F351 program. F351 has shown clinical efficacy as a treatment

CATALYST BIOSCIENCES, INC. -> GNI’s proprietary new chemical entity F351 program. F351 has shown clinical efficacy as a treatment · $7.5 million

Continent has operated profitability during the last 5 years while funding a clinical pipeline focused on other fibrosis indications, including F351 for hepatitis B virus (HBV)-associated fibrosis and non-alcoholic steatohepatitis (“NASH”).